Mounjaro™ (tirzepatide) injection is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As the first and only FDA-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide ...

Nov 8, 2023 · Zepbound™ (tirzepatide) injection is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m 2), or overweight (BMI ≥ 27 kg/m 2) with at …

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive ...

Jan 15, 2025 · Effective Jan. 1, Omvoh has successfully gained first-line biologic coverage** from two of the three largest pharmacy benefit managers. Through Lilly Support Services™, Lilly offers a patient support program including co-pay assistance for eligible, commercially insured patients.

Mar 8, 2024 · The FDA has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design of the TRAILBLAZER-ALZ 2 study, including its limited-duration dosing regimen that allowed patients to ...

Sep 13, 2024 · Lilly's partner Almirall S.A. has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including eczema, in Europe.

Dec 20, 2024 · Zepbound ® (tirzepatide) injection is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. It is also approved in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in ...

Oct 6, 2022 · The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need.

Sep 22, 2023 · RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 22, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Jardiance ® (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic ...

Dec 4, 2024 · Tirzepatide was approved by the U.S. FDA as Mounjaro ® for adults with type 2 diabetes to improve glycemic control on May 13, 2022, and as Zepbound ® for adults with obesity or with excess weight and weight-related medical problems on November 8, 2023.